AMD

View All

MedTech News for LumiThera, 3Spine and Teleflex
LumiThera’s US LIGHTSITE III Trial; First Patient Enrolled in Vascular Closure Device Study of Teleflex; Varian’s Flash Technology Clinical Trial, FAST-02; 3Spine’s MOTUS Device; Illumina’s Research Test to Detect Tumor Genome; Acutus Medical’s AcQCross Qx System

LumiThera Announced the Result of US LIGHTSITE III Trial of Non-neovascular Age-Related Macular Degeneration (AMD) Subjects Treated with Photobiomodulation (PBM) using the Valeda® Light Delivery System On June 22, 2022, LumiThera Inc., a commercial-stage medical device company offering photobiomodulation (PBM) t...

Find More

pharma-news-for-edwards-lineage-novartis-koios-medical
Edwards’ Sapien 3 with Alterra Prestent; Koios Medical’s breast, thyroid cancer-spotting AI; Lineage Collaborates with Genentech; Novartis, BeiGene ink deal

Edwards secures FDA approval for Sapien 3 with Alterra Prestent for Transcatheter Pulmonic Valve Replacement Edwards Lifesciences declared to receive approval from the U.S. Food and Drug Administration (FDA) to use the Edwards SAPIEN 3 transcatheter valve with the Alterra adaptive prestent (SAPIEN 3 with Alterra...

Find More

Johnson & Johnson
Antidepressant of J&J leads to FDA; SCLC model discloses; Genes and macular degeneration can disclose new treatment ways

The nasal antidepressant of Johnson & Johnson leads to FDA committee The antidepressant esketamine of Johnson & Johnson heads to FDA panel. This might be an end for the discoveries in novel therapies for the disorder. The intranasal, esketamine would be one of the first new approaches to treat the refrac...

Find More

Novartis on AMD drug; Hospira recall of vials; Takeda wraps up; FDA bans imports

Novartis takes on Regeneron with AMD drug that needs fewer doses than Eylea Last year, U.S. sales of Regeneron’s drug to treat age-related macular degeneration (AMD) came in at $3.3 billion—68% of the company’s total revenues—so it’s no wonder investors have been expressing some concerns about potential rivals movin...

Find More